CRBP Relative Valuation
CRBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRBP is overvalued; if below, it's undervalued.
Historical Valuation
Corbus Pharmaceuticals Holdings Inc (CRBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.57. The fair price of Corbus Pharmaceuticals Holdings Inc (CRBP) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：10.54
Fair
-1.78
PE
1Y
3Y
5Y
Trailing
Forward
-1.05
EV/EBITDA
Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current EV/EBITDA of -1.05. The 5-year average EV/EBITDA is -0.94. The thresholds are as follows: Strongly Undervalued below -5.99, Undervalued between -5.99 and -3.46, Fairly Valued between 1.59 and -3.46, Overvalued between 1.59 and 4.12, and Strongly Overvalued above 4.12. The current Forward EV/EBITDA of -1.05 falls within the Historic Trend Line -Fairly Valued range.
-0.99
EV/EBIT
Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current EV/EBIT of -0.99. The 5-year average EV/EBIT is -1.34. The thresholds are as follows: Strongly Undervalued below -7.12, Undervalued between -7.12 and -4.23, Fairly Valued between 1.55 and -4.23, Overvalued between 1.55 and 4.45, and Strongly Overvalued above 4.45. The current Forward EV/EBIT of -0.99 falls within the Historic Trend Line -Fairly Valued range.
177.93
PS
Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current PS of 177.93. The 5-year average PS is 77.83. The thresholds are as follows: Strongly Undervalued below -230.37, Undervalued between -230.37 and -76.27, Fairly Valued between 231.93 and -76.27, Overvalued between 231.93 and 386.03, and Strongly Overvalued above 386.03. The current Forward PS of 177.93 falls within the Historic Trend Line -Fairly Valued range.
-2.80
P/OCF
Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current P/OCF of -2.80. The 5-year average P/OCF is -2.57. The thresholds are as follows: Strongly Undervalued below -12.50, Undervalued between -12.50 and -7.54, Fairly Valued between 2.39 and -7.54, Overvalued between 2.39 and 7.36, and Strongly Overvalued above 7.36. The current Forward P/OCF of -2.80 falls within the Historic Trend Line -Fairly Valued range.
-2.25
P/FCF
Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current P/FCF of -2.25. The 5-year average P/FCF is -2.73. The thresholds are as follows: Strongly Undervalued below -9.66, Undervalued between -9.66 and -6.20, Fairly Valued between 0.73 and -6.20, Overvalued between 0.73 and 4.20, and Strongly Overvalued above 4.20. The current Forward P/FCF of -2.25 falls within the Historic Trend Line -Fairly Valued range.
Corbus Pharmaceuticals Holdings Inc (CRBP) has a current Price-to-Book (P/B) ratio of 1.45. Compared to its 3-year average P/B ratio of 6.91 , the current P/B ratio is approximately -78.98% higher. Relative to its 5-year average P/B ratio of 4.84, the current P/B ratio is about -70.01% higher. Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -78.77%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -82.15% , the current FCF yield is about -100.00% lower.
1.45
P/B
Median3y
6.91
Median5y
4.84
-30.10
FCF Yield
Median3y
-78.77
Median5y
-82.15
Competitors Valuation Multiple
The average P/S ratio for CRBP's competitors is 0.00, providing a benchmark for relative valuation. Corbus Pharmaceuticals Holdings Inc Corp (CRBP) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CRBP in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Corbus Pharmaceuticals Holdings Inc (CRBP) currently overvalued or undervalued?
What is Corbus Pharmaceuticals Holdings Inc (CRBP) fair value?
How does CRBP's valuation metrics compare to the industry average?
What is the current P/B ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Dec 05 2025?
What is the current FCF Yield for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Dec 05 2025?
What is the current Forward P/E ratio for Corbus Pharmaceuticals Holdings Inc (CRBP) as of Dec 05 2025?